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Men who have sex with men (MSM) and who engage in condomless anal intercourse with
casual partners are at high risk of acquiring sexually transmitted infections (STIs), but reli-
able epidemiological data are scarce. Studies on HIV pre-exposure prophylaxis (PrEP)
enrol MSM who indicate that they engage in behaviour that puts them at high risk of acquir-
ing HIV. Because they also screen for STIs at regular intervals, these studies may serve as
a valuable source to estimate incidence rates of STIs in this subpopulation of MSM.
Methods
We systematically searched for trials and observational studies of PrEP in MSM that reported
data on the incidence of STIs during the study period. Incidence rates were calculated as
events per 100 person-years (py) with 95% confidence intervals (CI). Data from individual
studies were pooled building subgroups along study types and geography. We performed
sensitivity analyses, including data only from studies that met pre-defined quality criteria.
Results
Twenty-four publications on 20 studies were included. The majority of studies reported that
sexual behaviour and/or STI incidence remained stable or decreased during the study
period. For syphilis, incidence rates ranged from 1.8/100py to 14.9/100py, the pooled esti-
mate was 9.1/100py (95%-CI: 7.7–10.9). Incidence rates for gonorrhoea and chlamydia of
any site ranged from 13.3/100py to 43.0/100py and 15.1/100py to 48.5/100py, respectively.
Considering only studies that met the criteria for sensitivity analysis yielded pooled esti-
mates of 39.6/100py (95%-CI: 32.9–47.6) and 41.8/100py (95%-CI: 33.9–51.5), respec-
tively. The overall estimate for hepatitis C incidence was 1.3/100py (95%-CI: 1.0–1.8).
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Conclusions
Despite partly heterogeneous results, the data depict high incidence rates of STIs among
MSM who engage in higher-risk sexual behaviours such as condomless sex with casual
partners. This subpopulation of MSM requires access to STI screening at close intervals. By
offering access to structures that provide regular STI monitoring and prompt treatment,
PrEP may not only decrease HIV incidence but also have beneficial effects in decreasing
the burden of STIs.
Introduction
Data on the epidemiology of sexually transmitted infections (STIs) suggest a high burden of
disease worldwide [1]. Increases in the incidence of chlamydia, gonorrhoea and syphilis infec-
tions have been observed in numerous countries, particularly among men who have sex with
men (MSM) [2–6]. At the same time, the decreasing susceptibility of bacterial pathogens such
as Neisseria gonorrhoeae [7–11] and Mycoplasma genitalium [12,13] to antimicrobials is
becoming a major public health problem, especially given evidence that the risk of HIV trans-
mission is higher in the presence of other STIs [14–17].
Reliable data on the incidence of STIs among sexual minorities are difficult to obtain [18–
20]. In some countries, reporting systems for STIs may include information on the probable
route of transmission. However, calculating incidence rates for STIs among MSM from these
population-based data can rely only on reported cases for the numerator and estimates of the
denominator, which is unknown (i.e., the total number of MSM at risk of acquiring an STI)
[21,22]. Therefore, from an epidemiological viewpoint, a more reliable method to generate
estimates of STI incidence rates in sexual minorities is to use incidence data from longitudinal
cohort studies.
In the present systematic review and meta-analysis, we aimed to generate effect estimates
for incidence rates of STIs in MSM who engage in sexual behaviours that put them at high risk
of acquiring STIs. To do so, we used data on the incidence of STIs diagnosed during the study
period in participants from studies on HIV pre-exposure prophylaxis (PrEP). PrEP is a bio-
medical form of primary HIV prevention that has been shown to be highly effective in clinical
trials [23–26] and cohort studies [27–35]. Most PrEP trials and cohort studies only enrol MSM
who indicate that they engage in behaviour that puts them at high risk of acquiring HIV,
which is usually defined in these studies as reporting having had condomless anal intercourse
within a specified amount of time with a specified minimum number of partners. Because they
also screen for STIs at regular intervals, these studies may serve as a valuable source of STI inci-
dence data in this subpopulation of MSM.
Materials and methods
We conducted a systematic review and meta-analysis of data on the incidence of STIs in pub-
lished trials and cohort studies of PrEP in MSM at risk of HIV infection. A review protocol
was developed and followed but not published (S1 File).
Eligibility criteria
Publications were eligible if they reported results from clinical studies of PrEP in MSM at risk
for HIV infection and had a follow-up period of at least three months. To be included, studies
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had to report the incidence of STIs other than HIV and provide sufficient data on the person-
years of follow-up to calculate incidence rates. Any form of testing for STIs had to be per-
formed at regular intervals; studies that relied exclusively on self-reported incidence data were
not included. We considered full-text publications and conference abstracts. Language was
restricted to English, French and German.
Information sources and search strategy
We searched Ovid MEDLINE, Embase and Cochrane CENTRAL on 28 September 2017 and
conducted an update search on 25 July 2018 covering the period from the inception of the data
base through the date of the search. Autoalerts for all searches were included through 1 August
2018. The full search strategies can be viewed in the online supplement (S1 File). Resource lim-
itations meant that authors were contacted for missing data only for studies that had been
included in the original search.
Study selection and data collection
We checked all identified records for eligibility using a two-step process, screening titles and
abstracts first, and assessing full texts of records included thereafter. Data were extracted by
two evaluators (RNW and CD). Disagreement was resolved by discussion or by involving a
third investigator (AN, MG). Apart from incident STI diagnoses and corresponding person-
years of follow up, data were extracted on study type and characteristics, baseline characteris-
tics of the sample, and any reported changes in sexual behaviour or STI incidence. We did not
extract data that were only presented graphically. As data from a randomised controlled trial
suggests that PrEP could have an effect on the incidence of genital herpes [36], we considered
data on genital herpes only if these were reported separately for placebo or non-intervention
arms. For data on hepatitis B, we chose the same approach since tenofovir is an established
medication for chronic hepatitis B.
Assumptions, simplifications and calculations
If incidence rates with 95% confidence intervals (95%-CIs) and the total person-years of fol-
low-up were not reported, we calculated person-years as follows: If possible, we multiplied the
number of participants per visit by the length of time since the previous visit, or by multiplying
the number of participants by the mean follow-up time. Where only the overall number of par-
ticipants at baseline and at the end of follow-up were reported and the number of participants
for each time point was missing, we calculated person-years by multiplying the number of par-
ticipants who completed the study plus half the number of participants who had not completed
the closing visit by the length of the follow-up period. For all of these approaches, we used the
number of incident diagnoses whenever possible; however, in some cases only the number of
participants infected was available.
Incidence rates were calculated as events per 100 person-years of follow-up. Assuming a
Poisson distribution, we used log incidence rates and corresponding standard errors to deter-
mine incidence rates with 95%-CIs. If no incident cases occurred during follow-up, we added
a correction of 0.5 to the number of cases and person-years of follow-up as described in similar
studies [37,38].
Synthesis of the results
STI incidence data were grouped according to study type and geography. We calculated pooled
estimates of the incidence rates and 95% CIs using a random effects model to account for
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methodological and clinical differences between the studies. Heterogeneity was quantified by
means of the Higgins’s I-squared test statistic [39]. All calculations were performed using Stata
SE 14 (metan command package).
Assessment of the quality of the data
In order to evaluate the quality of the data, three criteria were established: First, we evaluated
whether the data on incidence rates or numbers of incident STI diagnoses and person-years of
follow-up were explicitly reported or easy to calculate or interpret. Second, we assessed whether
studies reported having performed screening procedures for the detection of STIs during the
follow-up. To satisfy this quality criterion, studies had to explicitly state having performed
screening procedures at a minimum of six monthly intervals and in accordance with the Cen-
ters for Disease Control and Prevention (CDC) recommendations for STI screening in sexually
active MSM [40]. Third, we evaluated the size of each study, considering more than 500 person-
years of follow-up to be an indicator of higher quality incidence data.
Further analyses
To examine sources of heterogeneity, we separately evaluated subgroups along study design
and geography. We performed a sensitivity analysis for each outcome, only considering data
extracted from studies that explicitly reported incidence rates (or provided easy-to-interpret
data for numbers of incident diagnoses and person-years of follow-up) and that reported hav-
ing applied STI screening methods that met our quality criterion #2. We did not undertake
any formal tests of publication bias in our meta-analysis because our outcome of interest (i.e.,
STI incidence rates) was not an efficacy outcome that might have led to the selective publica-
tion of study results.
Results
Our literature search yielded 2416 records, of which 1581 remained after duplicates had been
removed. Of these, 1456 were excluded during the title and abstract screening, leaving 125
publications to be evaluated as full texts. Finally, 24 publications reporting the results of 20
studies were included. Fig 1 depicts the numbers of records identified, included and excluded
[41].
Study characteristics
The 20 studies were: three double-blind, placebo-controlled RCTs [23,24,26,42,43], one dou-
ble-blind, active-controlled RCT [44], one open-label RCT [25] with STI incidence data
derived from the PrEP group only, and 15 cohort studies [27–34,45–53]. A total of 11,918 par-
ticipants were enrolled in these studies, yielding a cumulative 11,686.0 person-years of follow-
up. Table 1 gives an overview of study types, inclusion criteria, sample sizes and baseline
characteristics.
Quality of data
Data on incidence rates for some or all of the reported STIs were directly reported or easy to
interpret in 14 studies [25,27–31,34,42,43,45–48,51–53]. Eighteen studies explicitly reported
the application of screening methods as recommended by the CDC for some or all of the STIs
assessed [24–31,33,34,42–47,50,51]. Six studies had at least 500 person-years of follow-up, ful-
filling our criterion for large study size [23,29–31,42,43,46,48,49]. Table 2 gives an overview of
our assessment of data quality for each study.
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Changes in sexual behaviour and STI incidence during the study period
Two RCTs [24,26] and four cohort studies [28,32,33,50] reported that sexual behaviour had
not changed with respect to condom use and/or the number of sexual partners. Two of these
studies [28,50] and one further cohort study [49] additionally reported no change in the inci-
dence of STIs. One retrospective cohort study [51] reported an increase in STI incidence com-
pared to the time before PrEP initiation. However, this increase was not significant after
adjusting for the number of screening visits. A decrease in the number of sexual partners and
instances of condomless anal intercourse was observed in an RCT [23] and its open-label
extension [31]. A smaller overall STI incidence in the second compared to the first half of the
study was reported in one cohort [34]. In contrast, decreasing rates of condom use were
reported in three cohort studies [30,47,52], and increasing incidence rates for STIs observed in
two cohort studies [27,29]. Four studies did not report on changes in sexual behaviour or STI
incidence during the follow-up [25,44–46].
Any STI
One active-controlled RCT [44] and seven cohort studies [27–29,33,34,49,51] reported data on
the incidence of any STI diagnosis, comprising a total of 2105.7 person-years (py) of follow-
up. One of these studies specifically reported the incidence of any bacterial STI diagnosis
(gonorrhoea, chlamydia or syphilis) [49]. Incidence rates ranged from 33.0/100py (95%-CI:
27.5–39.6) in the active-controlled RCT [44] to 99.8/100py (95%-CI: 82.6–120.6) in an Austra-
lian cohort study [27], yielding a pooled estimate of 72.4/100py (95%-CI: 58.8–89.1, I2 =
94.9%). The heterogeneity of the incidence rates remained high when only cohort studies
Fig 1. PRISMA flow diagram. Depicts the number of records identified, included and excluded, and the reasons for
exclusions.
https://doi.org/10.1371/journal.pone.0208107.g001
Incidence of STIs in MSM at substantial risk of HIV infection




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Incidence of STIs in MSM at substantial risk of HIV infection


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Incidence of STIs in MSM at substantial risk of HIV infection






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Incidence of STIs in MSM at substantial risk of HIV infection























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Incidence of STIs in MSM at substantial risk of HIV infection





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Incidence of STIs in MSM at substantial risk of HIV infection



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Incidence of STIs in MSM at substantial risk of HIV infection
PLOS ONE | https://doi.org/10.1371/journal.pone.0208107 December 3, 2018 11 / 24
conducted in North America [28,29,33,34,50,51] were considered [pooled estimate 64.4/100py
(95%-CI: 48.4–85.6), I2 = 95.9%]. One Dutch [49] and the above-mentioned Australian cohort
study [27] had comparable incidence rates [97.8/100py (95%-CI: 89.2–107.2) and 99.8/100py
Table 2. Evaluation of the quality criteria.
Author / Year (Name of the
study)
STI incidence data directly reported or easy to
interpret
Robust screening methods for detection
of STI
Large study size (> 500 person-
years)
Double-blind, placebo-controlled RCTs
Grant et al. 2010 [23];
Solomon et al. 2014 [43];









Hosek et al. 2013 [24]
(PrEPare)
- + -










Gulick et al. 2017 [44] - + -
Open-label, placebo-controlled RCT; STI incidence data derived from PrEP group only
McCormack et al. 2016 [25]
(PROUD)
+ + -
Cohort studies of PrEP users
Bristow et al. 2018 [45] + + -
Cotte et al. 2018 [45] + + +
Golub et al. 2016 [47]
(SPARK)
+ + -
Grant et al. 2014 [31]
(iPrEx_OLE)
+ + +
Grinsztejn et al. 2018 [32]
(PrEP Brasil)
- - -





Hosek et al. 2017 [34] + + -











Lalley-Chareczko et al. 2018 [50] - + -








Molina et al. 2017 [30]
(IPERGAY open-label extension)
+ (hepatitis C)
- (syphilis, gonorrhoea, chlamydia)
+ (gonorrhoea, chlamydia, syphilis)
- (hepatitis C)
+
Nguyen et al. 2018 [51] + + -
Noret et al. 2018 [52] + - -
Volk et al. 2015 [53]
(’Kaiser Cohort San Francisco’)
+ - -
+, quality criterion met; -, quality criterion not met
https://doi.org/10.1371/journal.pone.0208107.t002
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(95%-CI: 82.6–120.6), respectively]. Looking separately at the four cohort studies that fulfilled
our quality criteria for the sensitivity analysis [28,29,34,51], our estimates ranged from 66.4/
100py (95%-CI: 54.9–80.5) to 90.7/100py (95%-CI: 84.5–97.3), yielding an overall pooled esti-
mate of 84.4/100py (95%-CI: 75.6–94.2, I2 = 68.3%).
Syphilis
Three placebo-controlled RCTs [24,26,43], one active-controlled RCT [44], one open-label
RCT [25], and eight cohort studies [27,28,31–33,47,50,51] reported on incident cases of syphi-
lis, comprising a total of 7771.5 person-years of follow-up. Two studies reported on partici-
pants infected rather than number of infections, and re-infections may have been unreported
in these studies [44,50]. Considering all studies reporting on the incidence of syphilis, we cal-
culated a pooled estimate of 9.2/100py (95%-CI: 7.7–10.9, I2 = 65.7). Incidence rates ranged
from 1.8/100py (95%-CI: 0.3–12.9) in a cohort study of 15-to-17-year-old PrEP users [33] to
14.9/100py (95%-CI: 5.6–39.8) in an RCT of PrEP in 18 to 22 year old participants [24]. As the
person-years of follow-up were not directly reported in either of these two studies, these esti-
mates should be treated with caution. Looking separately at cohort studies (i.e., in which all
participants were on PrEP), the pooled estimate was 9.4/100py (95%-CI: 7.2–12.4, I2 = 68.2).
Considering only the seven studies that met the quality criteria for our sensitivity analysis
[25,27,28,31,43,47,51], we calculated a pooled estimate of 9.5/100py (95%-CI: 7.5–12.1, I2 =
79.7), see Fig 2. Looking separately at the estimates for different continents, the lowest pooled
incidence rate was seen in studies that included participants from Latin America by majority
[31,32,43] [7.4/100py (95%-CI: 6.7–8.2, I2 = 0.0)], and the highest incidence was seen in an
Australian cohort study [27] [13.1/100py (95%-CI: 7.7–22.1)].
Gonorrhoea and chlamydia
Data on the incidence of gonorrhoea and chlamydia were reported in three placebo-controlled
RCTs [23,24,26] one active-controlled RCT [44] one open-label RCT [25] and in eight cohort
studies [27–29,33,45,47,50,51]. Grant et al. 2010 reported only testing for urethral gonorrhoea
and chlamydia infection upon positive urine leukocyte esterase [23] and Lal et al. reported test-
ing for genital gonorrhoea only upon clinical suspicion [27]. For two studies, routine sampling
did not include the throat [44] or it remained unclear, whether this site was included [45]. In
one cohort study, screening tests only included anal and pharyngeal sites for gonorrhoea, and
anal and urethral sites for chlamydia [27]. Three studies reported on persons infected, not on
events of infection during follow-up [26,44,50]. In the following we have put the different ana-
tomical locations in boldface to improve readability.
One cohort study reported data on the combined outcome of urethral gonorrhoea and/or
chlamydia [47]. In 179.5 person-years of follow-up, 32 cases of urethral STIs were diagnosed,
leading to an incidence rate of 17.8/100py (95%-CI: 12.6–25.2).
Two placebo-controlled RCTs [23,24] and four cohort studies [29,33,45,51] reported data
on urethral gonorrhoea, with an overall follow-up of 3626.4 person-years. The incidence of
urethral gonorrhoea ranged from 1.3/100py (95%-CI: 0.9–1.8) in the RCT that only tested for
urethral gonorrhoea upon positive leukocyte esterase[23] to 6.4/100py (95%-CI: 3.1–13.5) in a
retrospective Canadian cohort study.[51] The pooled estimate was 3.3/100py (95%-CI: 1.6–7.0,
I2 = 88.4%). Looking separately at cohort studies, the pooled estimate was 4.3/100py (95%-CI:
2.3–8.0, I2 = 72.1%). Considering only the three cohort studies that met the quality criteria for
inclusion in the sensitivity analysis [29,45,51], the pooled estimate was 4.0/100py (95%-CI:
1.8–8.8, I2 = 81.3%).
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For the outcome of urethral chlamydia, additionally to the six above-mentioned studies
reporting on urethral gonorrhoea, one cohort study [27] reported data, resulting in a total of
3706.0 person-years of follow-up. Incidence rates ranged from 1.0/100py (95%-CI: 0.7–1.5) to
26.2/100py (95%-CI: 12.5–54.9), and the pooled estimate was 7.5/100py (95%-CI: 3.4–16.3, I2
= 94.9%). Among the cohort studies [27,29,33,45,51], heterogeneity was lower, yielding a
pooled estimate of 9.2/100py (95%-CI: 7.2–11.7, I2 = 31.6%). Considering the four cohort stud-
ies that met the criteria for inclusion in the sensitivity analysis [27,29,45,51], the overall esti-
mate for urethral chlamydia infection was 9.1/100py (95%-CI: 6.8–12.2, I2 = 48.7%).
Four studies reported on the combined incidence of rectal gonorrhoea and/or chlamydia
[25,27,47,50], with an overall follow-up of 564.8 person-years. Incidence rates from these
reports ranged from 38.3/100py (95%-CI: 31.2–46.9) in the PrEP group of an English open-
label RCT [25] to 70.0/100py (95%-CI: 55.8–87.7) in an Australian cohort study [27]. The two
PrEP cohorts from the US [47,50] showed similar incidence rates [pooled estimate 51.9/100py
(95%-CI: 43.1–62.5, I2 = 0)]. The pooled estimate from all studies was 52.6/100py (95%-CI:
39.6–69.7, I2 = 80.9%). Only considering the three studies that met the criteria for inclusion in
the sensitivity analysis [25,27,47], the estimate for the incidence of rectal gonorrhoea and/or
chlamydia was 51.1/100py (95%-CI: 36.5–71.5, I2 = 86.8%).
Five cohort studies reported the incidence of rectal gonorrhoea and rectal chlamydia sepa-
rately [27,29,33,45,51]. For the outcome of rectal gonorrhoea, 1136.1 person-years of follow-
Fig 2. Syphilis incidence rates by study type, higher quality data only (sensitivity analysis). Incidence rates are given as events per 100 person-years. CI,
confidence interval.
https://doi.org/10.1371/journal.pone.0208107.g002
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up were available; for rectal chlamydia 1072.4 person-years. Incidence rates for rectal gonor-
rhoea ranged from 9.3/100py (95%-CI: 6.8–12.7) to 29.9/100py (95%-CI: 21.1–42.2), yielding
a pooled estimate of 16.3/100py (95%-CI: 10.4–25.6, I2 = 87.2%). Considering the four studies
[27,29,45,51] for sensitivity analysis only, the pooled estimate was 17.4/100py (95%-CI: 10.6–
28.5, I2 = 89.8%). Incidence rates for rectal chlamydia ranged from 14.6/100py (95%-CI: 7.3–
29.1) to 42.4/100py (95%-CI: 36.7–49.0). The pooled estimate was 30.3/100py (95%-CI: 21.9–
42.0, I2 = 86.2%). Considering the four studies [27,29,45,51] for sensitivity analysis only, the
pooled estimate for rectal chlamydia was 33.4/100py (95%-CI: 24.3–46.1, I2 = 86.8%). For both
rectal gonorrhoea and rectal chlamydia, the separate analysis of geographic regions did not
show less heterogeneous results.
One placebo-controlled RCT [26], one head-to-head RCT [44], one open-label RCT with
data only derived from the PrEP group [25], and four cohort studies [27,28,45,51] reported on
gonorrhoea and chlamydia of any of the body sites tested. The cumulative follow-up was
2093.2 and 2057.2 person-years, respectively. The incidence of gonorrhoea of any site ranged
from 12.2/100py (95%-CI: 9.0–16.4) in an active-controlled RCT reporting the number of per-
sons infected during follow-up rather than reporting the number of events of infection [44] to
43.0/100py (95%-CI: 37.5–49.3) in the US PrEP Demonstration Project [28]. The pooled esti-
mate from all studies reporting this outcome was 27.1/100py (95%-CI: 19.1–38.4, I2 = 94.1%),
see Fig 3. Looking separately at cohort studies, the pooled estimate was 31.6/100py (95%-CI:
21.2–47.1, I2 = 91.3%). The heterogeneity of the incidence rates remained high when different
geographic regions were pooled separately. Three studies [25,28,51] had incidence data easily
accessible and reported applying proper screening procedures for these outcomes (nucleic
acid amplification tests performed on anal and throat swabs and urine samples). Considering
these studies only, the pooled estimate was 39.6/100py (95%-CI: 32.9–47.6, I2 = 57.6%).
For chlamydia of any site, incidence rates were similarly heterogeneous, ranging from 13.9/
100py (95%-CI: 10.5–18.4) in the active-controlled RCT [44] to 48.5/100py (95%-CI: 37.0–63.7)
in the Australian VicPrEP cohort [27]. The pooled estimate was 30.2/100py (95%-CI: 21.4–42.5,
I2 = 94.3%), see Fig 4. Looking separately at cohort studies, the pooled estimate was 40.5/100py
(95%-CI: 31.0–52.9, I2 = 84.3%). Only considering studies that met the criteria for the sensitivity
analysis, the pooled estimate was 41.8/100py (95%-CI: 33.9–51.5, I2 = 72.3%).
Mycoplasma and ureaplasma
No study reporting on the incidence of genital or rectal mycoplasma or ureaplasma infection
was identified.
Viral hepatitis
One placebo-controlled RCT [26], one open-label RCT [25], and seven cohort studies
[30,46,48,50–53] reported data on the incidence of hepatitis C (HCV) during a cumulative fol-
low-up of 3730.5 person-years. Of these studies, only five [25,30,46,51,52] reported using serol-
ogy assays to screen for HCV at regular interviews. In the study by McCormack et al. [25] this
applied only to participants who reported injecting or snorting drugs, fisting or the use of sex
toys. The lowest HCV incidence was reported in a Canadian retrospective cohort study with
zero events during 109 person-years of follow-up [51]. The highest HCV incidence rate was
reported for the Dutch AmPrEP cohort [48] and totalled 1.9/100py (95%-CI: 1.1–3.4). The
overall estimate for HCV incidence was 1.3/100py (95%-CI: 1.0–1.8, I2 = 0.0). Looking sepa-
rately at the cohort studies, the pooled estimate was almost identical. Although the incidence
rate of HCV in European studies was twice the incidence rate in North American studies, the
confidence intervals for these estimates overlapped, see Fig 5. Pooling data only from the
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sensitivity analysis sample [25,30,46] yielded a pooled estimate for HCV incidence of 1.2/
100py (95%-CI: 0.8–1.8, I2 = 0.0).
One RCT [26] reported no incident cases of hepatitis B during 175 person-years of follow-
up in the placebo group.
The incidence of hepatitis A was reported in one French cohort study [52]. Six cases were
diagnosed during a follow-up of 486 person-years, yielding an incidence rate of 1.2/100py
(95%-CI: 0.6–2.8).
Participants with at least one STI and other STIs reported
Six studies reported on the outcome ‘participants diagnosed with at least one STI’, and one
study each reported on anogenital warts, herpes simplex seroincidence, molluscum contagio-
sum and trichomonas. These data are reported in the online supplement (S2 File).
Discussion
The present meta-analysis aimed to generate estimates for incidence rates for various STIs among
MSM who engage in high-risk sexual behaviours, such as condomless anal intercourse with casual
partners. The results indicate that the incidence rates for STIs in this subgroup of MSM are high.
The incidence rate for a diagnosis with any STI was about 84/100py in the four cohort studies that
Fig 3. Gonorrhoea of any anatomical localisation by study type. Incidence rates are given as events per 100 person-years. CI, confidence interval.
https://doi.org/10.1371/journal.pone.0208107.g003
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met our criteria for higher-quality data. The bulk of diagnoses with any STI were due to chlamydia
and gonorrhoea infections at different anatomical sites. Here, rectal gonorrhoea, chlamydia or
both played a major role, with a pooled incidence rate of more than 50/100py. This is worrying
given the rising levels of antimicrobial resistance seen especially in Neisseria gonorrhoea in recent
years [7–11]. Although Mycoplasma genitalium infections have recently received increased atten-
tion as a difficult-to-treat STI [12] and epidemiological research partly supports screening for this
infection in populations at higher risk, such as MSM [12,54–56], no corresponding incidence data
were reported in the studies included in our meta-analysis.
Our overall estimate for the incidence rate of hepatitis C infections was 1.3/100py. This is
substantially higher than the incidence of 0.4 per 1000 persons per year seen in HIV-unin-
fected MSM and even the incidence of 7.8 per 1000 persons per year seen in HIV-positive
MSM reported in a recent meta-analysis that included both prospective and retrospective stud-
ies [57]. Recent research suggests that only a proportion of the hepatitis C infections in this
susceptible population are sexually transmitted and that practices involving intravenous or
nasal drug use play an important role [58,59]. Due to the potentially severe sequelae and the
high cost of treatment, our findings are worrying and suggest that policy makers may wish to
consider redoubling efforts at primary prevention in those at highest risk (e.g. routine screen-
ing, needle exchange programmes).
Fig 4. Chlamydia infections of any anatomical localisation by study type. Incidence rates are given as events per 100 person-years. CI, confidence
interval.
https://doi.org/10.1371/journal.pone.0208107.g004
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In the one study reporting incidence data for hepatitis A, a rate of 1.2/100py was observed.
While this is a high rate by any measure, it must be kept in mind that this French cohort study
was conducted during an outbreak of hepatitis A among MSM in several European countries
[60–65], including France [66]. Nevertheless, these data underline the importance of increas-
ing hepatitis A vaccination coverage in MSM, specifically in those who engage in sexual behav-
iour that puts them at high risk of acquiring HIV and other STIs.
Our study does not attempt to compare STI incidence rates among MSM taking PrEP ver-
sus MSM not taking PrEP. One such comparison has been performed previously [67]. How-
ever, the validity of such studies is questionable [68]. To be eligible to participate in clinical
trials of PrEP, participants had to be at high risk of infection with HIV (and hence other STIs)
already. Comparing this group of MSM to other MSM who are not at high risk, or to the over-
all population of MSM, will lead to predictable and meaningless results. Moreover, the fre-
quent testing for STIs in the PrEP studies will lead to an increase in the number of detected
STI diagnoses. Indeed, one of the PrEP cohort studies included reported that screening every
six months instead of quarterly would have delayed diagnosis of STIs in 24% of the participants
[47]. A retrospective cohort study that compared the incidence of STIs in the year before PrEP
initiation to the year after, found a significant increase only when the data were not adjusted
for testing frequency [51]. Two longitudinal studies comparing the incidence of STIs before
PrEP initiation to that during PrEP intake have reported mixed results: in the first, which
assessed the incidence of rectal STIs, no increase was seen [69], whereas in the second, a mod-
est but significant increase in ‘any STI’ and Chlamydia infections was reported [70]. Generally,
Fig 5. Hepatitis C incidence rates by geography. Incidence rates are given as events per 100 person-years. CI, confidence interval.
https://doi.org/10.1371/journal.pone.0208107.g005
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the majority of studies included in our meta-analysis reported either a stable or decreased risk-
behaviour and/or STI incidence during follow-up. This finding is supported by a recent case-
crossover study [71].
Since the participants included in the studies benefit directly from their participation (free
PrEP medication and STI testing), the follow-up may be more complete than in studies
designed to assess STI incidence rates in susceptible sexual minorities. However, using data
from PrEP trials and cohort studies to estimate STI incidence rates has a number of important
limitations. First, the majority of studies included in our meta-analysis were not designed spe-
cifically to assess STI incidence rates. We have attempted to address this limitation with our
sensitivity analysis. The results of this analysis generally support the validity of our approach.
A second limitation is our inclusion of data from heterogeneous study designs, as well as dif-
ferent regions and populations of MSM. While participants included in double-blind placebo-
controlled trials will not have known their group assignment, participants in the other types of
studies, particularly in PrEP cohort studies, will all have been aware that they were using PrEP.
This may have affected participants’ sexual risk taking behaviour and therefore their risk of
acquiring STIs. We have accounted for this by building subgroups according to each of the dif-
ferent study designs and presenting the data separately for these where appropriate. Neverthe-
less, when interpreting the overall effect estimates, readers will need to bear this limitation in
mind. The methodological and clinical heterogeneity is reflected by I-squared as a statistical
tests for heterogeneity. This was often high, with values exceeding 75%. In a few cases, hetero-
geneity was substantially reduced when we analysed subgroups separately according to study
design or region. While being at risk of acquiring HIV and therefore being eligible for PrEP
was the common inclusion criterion for most of the studies, the actual risk behaviour of the
participants may have varied between studies (and indeed over time) and may partly explain
the heterogeneity of our results. Because the risk behaviour of participants in the included
studies was not reported in ways that were consistent across the studies, comparing these risk
behaviours is difficult and stratifying them in meaningful ways not feasible. Further factors,
such as age and ethnicity of participants, may also partly explain high values of I-squared
obtained for some of our pooled estimates.
If the limitations of our study are borne in mind, our estimates of STI incidence rates
among MSM who are at high risk of STI infection can be helpful to policy makers and health
professionals working in the fields of primary prevention and clinical care. For example, our
estimates could be used to make recommendations on the frequency of STI screening and
access to it in this susceptible population. Indeed, offering PrEP to this group of MSM may not
only be a promising strategy to reduce the incidence of HIV. It could also help embed the tar-
get population into a comprehensive programme of frequent STI screening and treatment,
potentially reducing the incidence and prevalence of STIs in the medium term, as predicted by
a recent modelling study [72].
Conclusions
Despite the heterogeneous designs of the studies included in our meta-analysis and the hetero-
geneity of some of our results, our overall findings suggest that the incidence rates of various
STIs among MSM who engage in high-risk sexual behaviour is high. The high rates of gonor-
rhoea, chlamydia and hepatitis C infections in the included cohort studies raise particular con-
cerns. This subgroup of MSM can benefit from access to STI testing and treatment at close
intervals. The use of PrEP is a highly effective means of preventing HIV infection and should
be embedded in a comprehensive programme targeting primary and secondary prevention
and treatment of other STIs.
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